Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
about
The two faces of FBW7 in cancer drug resistance.Circulating markers for prognosis of hepatocellular carcinoma.Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3β-dependent protein degradation.Endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance in human ovarian cancer cells.A (90)Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy
P2860
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
@en
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
@nl
type
label
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
@en
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
@nl
prefLabel
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
@en
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
@nl
P2093
P2860
P1476
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
@en
P2093
Pierre Chan
Roberta Pang
Ronnie T Poon
Thomas Yau
P2860
P304
P356
10.1517/14656561003724705
P407
P577
2010-09-01T00:00:00Z